12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Latanoprostene bunod: Phase I started

Bausch + Lomb began the open-label, Japanese Phase I KRONUS trial to evaluate once-daily 0.024% latanoprostene bunod for 14 days in about 24 healthy male volunteers. Bausch...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >